Neurocrine Biosciences, Inc. reaffirmed sales guidance for the full year of 2024. For the year, company expects INGREZZA Net Product Sales of $2,100 million to $2,200 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
137.5 USD | -1.87% |
|
+1.78% | +4.35% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.35% | 13.84B | |
+16.44% | 122B | |
+18.94% | 113B | |
+18.81% | 26.22B | |
-25.37% | 19.01B | |
-19.95% | 15.71B | |
-20.20% | 15.22B | |
-47.37% | 14.72B | |
+59.91% | 14.58B | |
+108.13% | 10.4B |
- Stock Market
- Equities
- NBIX Stock
- News Neurocrine Biosciences, Inc.
- Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024